# Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer

> **NCT03926338** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 270 (estimated)

## Conditions studied

- Colorectal Cancer
- Mismatch Repair-deficient (dMMR)
- Microsatellite Instability-high (MSI-H)
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Neoadjuvant toripalimab plus celecoxib for 6 cycles
- **DRUG:** Neoadjuvant toripalimab monotherapy for 6 cycles
- **DRUG:** Neoadjuvant toripalimab plus celecoxib for 12 cycles
- **DRUG:** Neoadjuvant toripalimab monotherapy for 12 cycles
- **DRUG:** Toripalimab plus celecoxib as neoadjuvant or definitive therapy

## Key facts

- **NCT ID:** NCT03926338
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-05-10
- **Primary completion:** 2027-04-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03926338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03926338, "Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03926338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*